Mixed ethnicity male talking on smartphone, not actual Serostim® patient

Access and Support

Enrollment in the Serostim® Patient AXIS Center® is fast and easy!

The Patient AXIS Center® offers comprehensive access and treatment support, including help with prior authorizations as well as financial assistance for eligible patients. It’s easier than ever to enroll your patients!

 

Learn more
Serostim® Patient AXIS Center logo

A smoother, more efficient path to patient support

It’s easier than ever to get started with Serostim®

Patients registered with the Serostim® Patient AXIS Center® often receive prior authorization decisions faster and with more favorable outcomes.

Your eligible patients can benefit from an array of Serostim® patient support services, including:

  • Serostim® copay card and patient financial assistance programs
  • Assistance with Serostim® prior authorization requests
  • A dedicated Case Manager
  • Field reimbursement managers to assist with the process and provide education for your team
  • Help with product-specific questions
  • Virtual injection training*

*An injection training order is required. If injection training is requested, the patient’s provider will be contacted to create the order prior to training being scheduled.

Eligible patients pay $0†

Serostim® copay card

Patients can save with the Serostim® patient copay card†

  • Decrease or potentially eliminate out-of-pocket costs†
  • Card can be used at all pharmacies in the Serostim® Secured Distribution Pharmacy Network
  • For a list of pharmacies, visit Serostim.com/PharmacyList

Help your patients start saving on Serostim® today!

 

Download copay card Activate an existing card

Serostim® Patient Assistance Program

  • Eligible patients will receive Serostim® at no cost†
  • Patients must meet certain financial, medical, and other criteria to be eligible
  • Patients who receive drug benefits for Medicaid, Medicare, or other federal or state programs are not eligible

 

†For eligible commercially or privately insured patients.

  • Patients must have a prescription drug benefit that covers Serostim® and a valid Serostim® prescription
  • Patients may not use the card if their private insurance, HMO, or other health or pharmacy benefit program paid for the entire Serostim® prescription
  • This is not an insurance program
  • Patients may not combine this card with any other rebate, coupon, free trial, or similar offer
  • Void in any state where prohibited by law, taxed, or otherwise restricted
  • EMD Serono reserves the right to rescind, revoke, or amend this offer at any time without notice

A user-friendly guide to streamlined patient enrollment

Visual step-by-step instructions to efficiently guide you through the enrollment process

  • Useful tips for submitting prior authorization requests and filing appeals
  • Overview of patient information and essential documentation
  • Common access challenges to avoid
Download brochure

Introducing the Patient AXIS Center® Care Team:

Green telephone receiver icon representing Serostim® product support specialists

Enrollment is fast and easy!

To learn more or speak to your dedicated Case Manager, call the Patient AXIS Center® at 1-877-714-AXIS (2947)

Monday through Friday, 8 am-8 pm ET

Call the PATIENT AXIS Center®

Important Safety Information and Indication

Expand

CONTRAINDICATIONS

Acute Critical Illness:  Serostim® (somatropin) should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure.

Active Malignancy: Somatropin is contraindicated in the presence of active malignancy.  Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Discontinue somatropin if there is evidence of recurrent activity.

Hypersensitivity: Serostim® is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported.

Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.

WARNINGS AND PRECAUTIONS

Acute Critical Illness: Increased mortality (42% vs 19% in somatropin compared to placebo treated) in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin.

Concomitant Antiretroviral Therapy: Somatropin has been shown to potentiate HIV replication in vitro, and there was no increase in virus production when antiretroviral agents were added to the culture medium. No significant somatropin-associated increase in viral burden was observed.  All patients received antiretroviral therapy for the duration of treatment during Serostim® clinical trials.

Neoplasms: Patients with preexisting tumors should be monitored for progression or reoccurrence. Monitor patients on somatropin therapy carefully for preexisting nevi.

Impaired Glucose Tolerance/Diabetes: Patients with other risk factors for glucose intolerance should be monitored closely during Serostim® therapy. Cases of new onset impaired glucose tolerance, new onset type 2 diabetes, and exacerbation of preexisting diabetes have been reported in patients receiving Serostim®. Some patients developed diabetic ketoacidosis and diabetic coma and, in some, improved when Serostim® was discontinued and in others persisted. Some of these patients required initiation or adjustment of antidiabetic treatment.

Intracranial Hypertension: Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported usually within the first 8 weeks of somatropin therapy and rapidly resolved after stopping or reducing the somatropin dose. Funduscopic examination should be performed prior to initiating treatment with somatropin and periodically during treatment. If papilledema is observed, treatment should be stopped and restarted at a lower dose after IH-associated symptoms have resolved.

Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs.

Fluid Retention/Carpal Tunnel Syndrome: Increased tissue turgor (swelling, particularly in the hands and feet) and musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with Serostim®, but may resolve spontaneously, with analgesic therapy, or after reducing the frequency of dosing. Carpal tunnel syndrome may occur and if the symptoms of carpal tunnel do not resolve by decreasing the weekly number of doses, it is recommended that Serostim® treatment be discontinued.

Skin Atrophy: Rotate the injection site to avoid tissue atrophy.

Pancreatitis: Cases of pancreatitis have been reported rarely. Consider pancreatitis in patients who develop persistent severe abdominal pain.

ADVERSE REACTIONS

In clinical trials in HIV‑associated wasting or cachexia the most common adverse reactions (incidence >5%) were arthralgia, myalgia, peripheral edema, arthrosis, nausea, paresthesia, generalized edema, gynecomastia, hypoesthesia and fatigue.

SPECIAL POPULATIONS: 

Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in human milk. The safety and effectiveness of somatropin in pediatric patients with HIV have not been established.  Clinical studies did not include sufficient numbers of subjects > 65 to determine a response different from that of younger patients. Studies have not been conducted in patients with hepatic or renal impairment. Gender-based analysis is not available.

INDICATIONS AND USAGE

Serostim® (somatropin) for injection is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.

Please click here for full Prescribing Information.

Important Safety Information and Indication

CONTRAINDICATIONS

Acute Critical Illness:  Serostim® (somatropin) should not be initiated in patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure.

Active Malignancy: Somatropin is contraindicated in the presence of active malignancy.  Any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy with somatropin. Discontinue somatropin if there is evidence of recurrent activity.

Hypersensitivity: Serostim® is contraindicated in patients with a known hypersensitivity to somatropin or any of its excipients. Systemic hypersensitivity reactions have been reported.

Diabetic Retinopathy: Somatropin is contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy.

WARNINGS AND PRECAUTIONS

Acute Critical Illness: Increased mortality (42% vs 19% in somatropin compared to placebo treated) in patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure has been reported after treatment with pharmacologic amounts of somatropin.

Concomitant Antiretroviral Therapy: Somatropin has been shown to potentiate HIV replication in vitro, and there was no increase in virus production when antiretroviral agents were added to the culture medium. No significant somatropin-associated increase in viral burden was observed.  All patients received antiretroviral therapy for the duration of treatment during Serostim® clinical trials.

Neoplasms: Patients with preexisting tumors should be monitored for progression or reoccurrence. Monitor patients on somatropin therapy carefully for preexisting nevi.

Impaired Glucose Tolerance/Diabetes: Patients with other risk factors for glucose intolerance should be monitored closely during Serostim® therapy. Cases of new onset impaired glucose tolerance, new onset type 2 diabetes, and exacerbation of preexisting diabetes have been reported in patients receiving Serostim®. Some patients developed diabetic ketoacidosis and diabetic coma and, in some, improved when Serostim® was discontinued and in others persisted. Some of these patients required initiation or adjustment of antidiabetic treatment.

Intracranial Hypertension: Intracranial hypertension (IH) with papilledema, visual changes, headache, nausea, and/or vomiting has been reported usually within the first 8 weeks of somatropin therapy and rapidly resolved after stopping or reducing the somatropin dose. Funduscopic examination should be performed prior to initiating treatment with somatropin and periodically during treatment. If papilledema is observed, treatment should be stopped and restarted at a lower dose after IH-associated symptoms have resolved.

Severe Hypersensitivity: Serious systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with postmarketing use of somatropin products. Patients and caregivers should be informed that such reactions are possible and that prompt medical attention should be sought if an allergic reaction occurs.

Fluid Retention/Carpal Tunnel Syndrome: Increased tissue turgor (swelling, particularly in the hands and feet) and musculoskeletal discomfort (pain, swelling and/or stiffness) may occur during treatment with Serostim®, but may resolve spontaneously, with analgesic therapy, or after reducing the frequency of dosing. Carpal tunnel syndrome may occur and if the symptoms of carpal tunnel do not resolve by decreasing the weekly number of doses, it is recommended that Serostim® treatment be discontinued.

Skin Atrophy: Rotate the injection site to avoid tissue atrophy.

Pancreatitis: Cases of pancreatitis have been reported rarely. Consider pancreatitis in patients who develop persistent severe abdominal pain.

ADVERSE REACTIONS

In clinical trials in HIV‑associated wasting or cachexia the most common adverse reactions (incidence >5%) were arthralgia, myalgia, peripheral edema, arthrosis, nausea, paresthesia, generalized edema, gynecomastia, hypoesthesia and fatigue.

SPECIAL POPULATIONS: 

Somatropin should be used during pregnancy only if clearly needed and with caution in nursing mothers because it is not known whether somatropin is excreted in human milk. The safety and effectiveness of somatropin in pediatric patients with HIV have not been established.  Clinical studies did not include sufficient numbers of subjects ≥ 65 to determine a response different from that of younger patients. Studies have not been conducted in patients with hepatic or renal impairment. Gender-based analysis is not available.

INDICATIONS AND USAGE

Serostim® (somatropin) for injection is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary.

Please click here for full Prescribing Information.

Emd Serono logo

Cookie Settings

This site is intended for U.S. healthcare professionals only and governed by U.S. laws and government regulations.
Use and access of this site are subject to the terms and conditions set out in our Legal Statement and Privacy Policy.

©2024 Merck KGaA, Darmstadt, Germany or its affiliates. All rights reserved.
EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada.
Serostim and the AXIS Center are registered trademarks of Merck KGaA, Darmstadt, Germany or its affiliates.

US-SER-00244 07/24 6.0

You are about to leave Serostim.com and are being redirected to another website. Click "Return" to keep browsing Serostim.com. To continue to the new website, click "Continue."

Continue to site
Return to Serostim.com